Copenhagen, 30 November 2009 - On 11 November 2009, NeuroSearch A/S (NEUR)
completed a share offering with preemptive rights for the company's existing
shareholders. The offering was fully subscribed, resulting in the issue of
7,141,678 new shares with a nominal value of DKK 20 each.

Pursuant to section 6 of Executive Order no. 1273 of 16 December 2008 on
Issuers' Disclosure Obligations, it is hereby announced that at the end of
November 2009 the total nominal value of NeuroSearch A/S' share capital is DKK
487,590,160 distributed on 24,379,508 shares with a nominal value of DKK 20
each corresponding to 487,590,160 votes.


Flemming Pedersen
CEO



Contact persons:

Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103



About NeuroSearch - Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform, focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline (GSK), and a license collaboration with Abbott. The drug
pipeline comprises eight clinical (Phase I-III) development programmes:
Huntexil® (pridopidine) for Huntington's disease (Phase III), tesofensine for
obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with
Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias
in Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for
anxiety/depression (Phase I) and NSD-721 for social anxiety disorder (Phase I)
in partnership with GSK. In addition, NeuroSearch has a broad portfolio of
preclinical drug candidates and holds equity interests in several biotech
companies.

fonds.60-09 - share capital status_november 2009 - uk.pdf